» Articles » PMID: 26965690

Structure and Function of Fbxo7/PARK15 in Parkinson's Disease

Overview
Specialty Biochemistry
Date 2016 Mar 12
PMID 26965690
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Fbxo7/PARK15 has well-defined roles, acting as part of a Skp1-Cul1-F box protein (SCF)- type E3 ubiquitin ligase and also having SCF-independent activities. Mutations within FBXO7 have been found to cause an early-onset Parkinson's disease, and these are found within or near to its functional domains, including its F-box domain (FBD), its proline rich region (PRR), and its ubiquitinlike domain (Ubl). We highlight recent advances in our understanding of Fbxo7 function in Parkinson's disease, with respect to these mutations and where they occur in the Fbxo7 protein. We hypothesize that many of Fbxo7 functions contribute to its role in PD pathogenesis.

Citing Articles

A sporadic Parkinson's disease model via silencing of the ubiquitin-proteasome/E3 ligase component, SKP1A.

Fishman-Jacob T, Youdim M J Neural Transm (Vienna). 2023; 131(6):675-707.

PMID: 37644186 PMC: 11192832. DOI: 10.1007/s00702-023-02687-6.


FBXO7, a tumor suppressor in endometrial carcinoma, suppresses INF2-associated mitochondrial division.

Zhang H, Zhao Y, Wang J, Li J, Xia J, Lin Y Cell Death Dis. 2023; 14(6):368.

PMID: 37344480 PMC: 10284917. DOI: 10.1038/s41419-023-05891-0.


Identification of Biomarkers Associated With CD8+ T Cells in Coronary Artery Disease and Their Pan-Cancer Analysis.

Zhao S, Wu Y, Wei Y, Xu X, Zheng J Front Immunol. 2022; 13:876616.

PMID: 35799780 PMC: 9254733. DOI: 10.3389/fimmu.2022.876616.


Mitochondrial Neurodegeneration.

Zeviani M, Viscomi C Cells. 2022; 11(4).

PMID: 35203288 PMC: 8870525. DOI: 10.3390/cells11040637.


Mechanisms That Activate 26S Proteasomes and Enhance Protein Degradation.

Goldberg A, Kim H, Lee D, Collins G Biomolecules. 2021; 11(6).

PMID: 34067263 PMC: 8224753. DOI: 10.3390/biom11060779.